Formula I Pluripotent Modulators Inhibiting NF-kB and Inflammasome Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Classical anti-inflammatory drugs, including NSAIDs and steroids, are ineffective or have adverse effects in treating chronic diseases such as cardiovascular disease, type 2 diabetes, chronic kidney disease, Alzheimer's, and cancer, highlighting the need for alternative anti-inflammatory treatments for low-grade chronic inflammation.
Innovation Solution
Administration of a therapeutically effective amount of a compound of Formula I or its pharmaceutically acceptable salt, which inhibits NF-κB-dependent gene expression and inflammasome activation, thereby reducing inflammation and improving conditions like organ transplant rejection and chronic inflammatory diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If classical anti-inflammatory drugs (NSAIDs and steroids) are used to treat chronic diseases, then inflammation is reduced, but adverse effects occur and treatment effectiveness is limited
Solution Approach 1:
The patent applies parameter changes by developing compounds with modified chemical structures (Formula I compounds) that alter the pharmacological parameters of anti-inflammatory agents. These structural modifications enable selective inhibition of inflammatory pathways (NF-κB and inflammasome) while avoiding the adverse effects associated with classical NSAIDs and steroids, thus improving treatment reliability for chronic diseases
Solution Approach 2:
The patent uses intermediaries by introducing novel chemical compounds (Formula I) that act as mediators between the inflammatory pathways and therapeutic effect. These compounds selectively target and modulate specific inflammatory mechanisms (NF-κB-dependent gene expression and inflammasome activation) without triggering the harmful side effects of traditional anti-inflammatory drugs
2Ease of operation
If classical anti-inflammatory drugs are used, then some inflammatory symptoms are relieved, but they show no benefit or have adverse effects in treating chronic non-transmissible diseases
Solution Approach 1:
The patent applies local quality by designing compounds that exert selective anti-inflammatory effects at specific molecular targets (NF-κB and inflammasome pathways) rather than broad-spectrum suppression. This localized action at the molecular level provides symptom relief while avoiding the systemic adverse effects that prevent benefit in chronic disease treatment
Solution Approach 2:
The patent segments the anti-inflammatory mechanism into distinct targetable pathways (NF-κB-dependent gene expression and inflammasome activation). By developing compounds that specifically inhibit these segmented pathways, the invention achieves effective symptom relief and disease modification without the harmful effects of non-selective classical anti-inflammatory drugs
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound effectively reduces inflammation and improves conditions such as organ transplant rejection and chronic inflammatory diseases by inhibiting NF-κB-dependent gene expression and inflammasome activation, demonstrating greater potency than salicylic acid in preclinical studies.
Implementation Method 1
the compound of Formula I... which inhibits NF-κB-dependent gene expression and inflammasome activation, thereby reducing inflammation
Implementation Method 2
the compound of Formula I... which inhibits NF-κB-dependent gene expression and inflammasome activation, thereby reducing inflammation
Data Source
AI summary
Methods of treating acute and chronic inflammatory conditions, tissue transplant rejection, and/or organ transplant rejection comprising administering to a subject in need thereof a therapeutically effective amount of a pluripotent anti-inflammatory and metabolic modulators optionally in combination with one or more secondary therapeutic agents and pharmaceutical compositions thereof.